Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands ...

El Monte-based lab testing and pharmaceutical company Fulgent Genetics Inc. last month simultaneously announced a pair of ...

Fulgent Genetics, Inc. FLGT recently entered into an agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx — two well-known pathology testing companies — in a combined ...

Fulgent Genetics has signed a definitive agreement to buy specific assets of Bako Diagnostics and to acquire StrataDx, two US-based laboratories, for a combined purchase price of around $55.5m.

Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics continues to build upon its laboratory services platform both ...

ATLANTA, July 24, 2018 /PRNewswire/ -- Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced today the appointment of Ted Hull as Chief Executive Officer, effective ...

The acquisition is expected to close during the first half of 2026 Fulgent Genetics is a California-based drug developer and provider of laboratory services Ming Hsieh serves as chairman and CEO of ...

Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a ...